Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

Core Insights - The U.S. Securities and Exchange Commission (SEC) has declared effective the registration statement on Form F-4 for the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., marking a significant milestone in the merger process [1][3][5] Company Overview - NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders [5][6] - Kadimastem Ltd. is an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes [6] Merger Details - The merger will create a new entity named NewCelX Ltd., which will be publicly traded on Nasdaq under the ticker "NCEL" [3][5] - This merger combines Kadimastem's cell therapy platforms with NLS's expertise in small-molecule therapies, aiming to enhance the therapeutic scope in CNS disorders and metabolic diseases [7] Clinical and Strategic Highlights - Kadimastem is preparing to initiate a Phase 2a clinical trial of AstroRx® for ALS treatment, with global trial site selection and regulatory preparations underway [7] - The IsletRx diabetes program, developed in collaboration with iTolerance, has received support from the BIRD Foundation following a successful Pre-IND meeting with the FDA [7] - The merger is expected to strengthen the global position of the combined company and provide access to U.S. capital markets [5][7]